

## Date: 17 October 2019 AGREEMENT BETWEEN ESPT AND SPPPT - Russian Federation

This document defines a collaborative agreement between:

- 1. The European Society of Pharmacogenomics and Personalised Therapy (ESPT)

  Registered at University of Loraine UMR INSERM U1122, IGE-PCV 30 rue Loinnois, 54000

  NANCY, France. Executive Office Via Carlo Farini 81, 20159 Milan, ITALY. Email: office@esptnet.eu
- 2. Society of Pharmacogenetics, Pharmacokinetics and Personalized therapy (SPPPT)
  Registered at Malaya Nikitskaya St., 31, bldg. 1, 121069, Moscow, RUSSIAN FEDERATION.
  Email: Pharmacogenetics, Pharmacokinetics and Personalized therapy (SPPPT)
  Registered at Malaya Nikitskaya St., 31, bldg. 1, 121069, Moscow, RUSSIAN FEDERATION.

The organizations enter this agreement to foster their cooperation for advancing basic/clinical research, and translation of this into clinical practice in the field of Pharmacogenomics and Personalised Medicine.

## ESPT (European Society of Pharmacogenomics and Personalized Therapy)

The European Society of Pharmacogenomics and Personalised Therapy is a non-profit-making organisation. Its objective is to promote training and research in pharmacogenomics and personalised therapy, in order to produce quality-controlled information for applications in clinical practice and for patients. It aims to facilitate contact between all those sharing its objectives, in particular those working in Europe. The Society will encourage and endeavour to integrate fundamental multidisciplinary approaches to research and transform them into clinical benefits, both for professional training and education of the general public, in all the areas of human pharmacogenomics, clinical pharmacology, laboratory medicine and personalised medicine. The strategic plan, mission & vision of ESPT can be found at: www.esptsociety.eu.

Created in 2010, ESPT represents individual members, national societies' members, corporate members, research group members and students in the field mainly from European countries, but not excluding other parts of the world. Scientific Advisory Board Members are completing the membership. ESPT concentrates its activities in 4 divisions: Clinical Implementation Division, Scientific Division, Education and Course Division and the Communication Division.

Every two years, an ESPT congress will be organized, location to be decided by the ESPT Board with in the alternate year an ESPT summer school. Target audience is health care professionals, clinical (bio)chemists, geneticists, pharmacologists, research groups, pharma- and diagnostic industry, regulatory bodies and other relevant stakeholders in the field of pharmacogenomics and personalized therapy.

## SPPPT (Society of Pharmacogenetics, Pharmacokinetics and Personalized therapy)

Organization is created to provide services in scientific and educational fields of clinical pharmacology and rational pharmacotherapy from the standpoint of personalized medicine. Organization achieve objectives in accordance with the legislation of the Russian Federation:

- Creation favorable conditions for the improvement of medical and pharmaceutical education;
- Activities to provide information, representation services, consultations in the field of medical science, practice and organization of health care;
- Creation of material and technical base of the organization promoting creation of educational means, acquisition of diagnostic, medical and scientific equipment, information materials rendering assistance to activity of health care experts;
- Assistance in development and study of medicines personalization new approaches;
- Information support and providing of specialists in field of clinical pharmacology, rational pharmacotherapy and personalized medicine.

4-12-2049

- Dissemination of information about latest medical science achievements in field of clinical pharmacology and rational pharmacotherapy from the perspective of personalized medicine;
- Organization and holding of medical scientific conferences and congresses, symposia, forums, congresses, discussions, meetings, exhibitions and presentations (including abroad) in order to provide information about world achievements in field of clinical pharmacology and rational pharmacotherapy from the perspective of personalized medicine;
- Involvement of leading scientists, specialists, practitioners, heads of relevant departments, representatives of professional societies and associations in field of medicine and health care for participation in organized events to provide comprehensive coverage of topical issues of medical science and practice;
- Participation in research activities in field of medical educational innovations;
- Organization and support of new technologies, software and other products creation in Internet and information technology;
- Participation in associations, foundations with state and non-governmental information, scientific, educational, medical and commercial organizations (Russian and foreign);
- Participation in development and promotion of improvement of legal framework governing medical education and health care (including medicines), participation in state and non-state programs implementation in relevant theme of organization;
- Research activities in field of clinical pharmacology and rational pharmacotherapy from the
  perspective of personalized medicine (participation in organization of observational programs,
  clinical trials of drugs and development algorithms for treatment and diagnosis);
- Providing knowledge about diseases, diagnosis and treatment to patients (including patient training lectures and conferences);
- Assistance in development of socially-oriented health care.

Created in 28 December 2016, SPPPT currently represents 48 members. Membership list attached.

## AGREEMENT

The respective organizations **ESPT** and **SPPPT express an interest** on collaboration for the development of Pharmacogenomics and Personalized Medicine in Europe. Both societies agreed that:

ESPT will consider SPPPT to be the official organization representative of that country

is willing to give auspices to **SPPPT** events on requests. ESPT is willing to organise joint sessions national congresses/symposiums/conferences of the **SPPPT**, if there is mutual interest and sufficient available resources. ESPT may occupy a stand in their exhibition.

is giving the right for SPPPT for 1 vote per 50 members at the ESPT General Assembly

is giving the right to include the **SPPPT** logo on the first page of the official journal of ESPT, currently being the Journal Drug Metabolism and Personalized Therapy (DMPT).

**ESPT** will offer to all **SPPPT** members access to information by mail or via ESPT web page.

**ESPT** will allow registration rates for all **SPPPT** members at the ESPT congresses and summer schools at the level of ESPT member.

In this agreement, SPPPT will pay membership dues to ESPT, being: individual membership fee for the SPPPT leader(s) (currently € 85), and in addition € 5 per SPPPT member. The membership list will be provided by SPPPT to ESPT (office@esptnet.eu) and will be updated yearly in January to allow calculations.

4-12-207

of the membership fees.

SPPPT will transfer ESPT information, sent to the SPPPT president, to all members.

**SPPPT** will encourage their members to participate in activities of ESPT. **SPPPT** members are encouraged to send abstracts to congresses of ESPT.

**SPPPT** may propose sessions, speakers and experts for the ESPT congresses and summer schools. There will be, however, no guarantee of privileged selection.

The president of **SPPPT** is a full ESPT member and will be voting at the ESPT General Assembly. National Societies members will have no voting rights and no access to the restricted area on the website. For this, they need to upgrade to full member. The president of **SPPPT** may appoint a representative to cast the **SPPPT** vote instead of the president, to be confirmed in writing to ESPT executive office.

This agreement will be active from date of signing, and will be prolonged automatically every year, unless written termination of the collaboration by either of two partners with a three-month notice or a 1-year failure of paying membership dues. Membership runs from January 1 to December 31.

Prof. dr. Ron All yan Schaik

Date: 4-12/2010